Trial Profile
A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs SB 728 HSC (Primary) ; Busulfan
- Indications HIV-1 infections
- Focus Adverse reactions
- 02 Jan 2024 Planned End Date changed from 10 Dec 2023 to 13 Aug 2024.
- 16 Oct 2023 According to a Fortress Biotech Media Release, the trial will initially enroll at City of Hope and University of California at San Diego.
- 16 Oct 2023 According to a Fortress Biotech Media Release, the California Institute for Regenerative Medicine recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial.